^
    Back
    Association details:
    Biomarker:HER-2 L755S
    Cancer:Gastric Cancer
    Drug:WZ4002 (EGFR inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    New
    Source:
    PLoS One
    Title:

    Differential Sensitivity of ERBB2 Kinase Domain Mutations towards Lapatinib

    Published date:
    10/28/2011
    Excerpt:
    Lapatinib-resistant ERBB2 mutations were found to be highly resistant towards AEE788 treatment but remained sensitive towards the dual irreversible inhibitors CL-387785 and WZ-4002.
    DOI:
    10.1371/journal.pone.0026760